Pharmaceuticals
WuXi Biologics Announces Manufacturing Partnership with InflaRx to Advance Gohibic for the Treatment of Certain Critically Ill COVID-19 patients
* WuXi Biologics is the manufacturing partner of InflaRx for Gohibic (vilobelimab), a first-in-class monoclonal anti-C5a antibody. * InflaRx received emergency use authorization (EUA) from the FDA for Gohibic (vilobelimab) for the treatment of certain critically ill COVID-19 patients in April ...
2023-05-16 16:00
2514
LG Chem Targets Sixfold Sales Growth in Battery Materials to KRW 30 Trillion by 2030
- Will expand sales portion in battery materials, sustainability business and innovative new drugs - Aims to accelerate in reaching net zero by 2050 by proactively building an integrated low-carbon management system SEOUL, South Korea, May 15, 2023 /PRNewswire/ -- LG Chem today announced i...
2023-05-16 09:34
3245
CMUH Smart Medicine System Assisted the ARDS Specialist Team Successfully Reversed the Patient's Critical Condition
TAICHUNG,Taiwan, May 15, 2023 /PRNewswire/ -- After the worldwide COVID-19 pandemic, most people suffered from mild disease, and "Acute Respiratory Distress Syndrome (ARDS)" is common for those critical COVID-19 patients. The 46-year-old of Ms. Chang, who had hypertension and nephropathy, accepte...
2023-05-15 20:30
2158
Gracell Biotechnologies Initiates Investigational Study Evaluating GC012F for Treatment of Refractory Systemic Lupus Erythematosus (SLE)
Gracell announces start of investigator-initiated trial to expand clinical evaluation of FasTCAR-T GC012F into autoimmune disease GC012F pioneers the use of CD19/BCMA dual-targeting CAR-T in SLE, aiming for deeper and wider depletion of autoantibodies producing B-cells and plasma cells SAN DIEGO...
2023-05-15 19:00
2693
LaNova Medicines Announces Global Exclusive License Agreement with AstraZeneca for LM-305, a Novel GPRC5D-Targeting Antibody Drug Conjugate
SHANGHAI, May 12, 2023 /PRNewswire/ -- LaNova Medicines Ltd. ("LaNova Medicines") announced today it has entered into an exclusive license agreement with AstraZeneca (LSE/STO/Nasdaq: AZN), for LM-305, a pre-clinical stage antibody drug conjugate (ADC) targeting G protein-coupled receptor, class C...
2023-05-12 23:30
4445
Crystal Formulation Services' GMP Manufacturing Facility Successfully Passes the Remote Audit by US Client, Marking a Key Milestone for Its International Expansion
SUZHOU, China, May 12, 2023 /PRNewswire/ -- Today, Crystal Pharmatech announced that the GMP manufacturing facility of their CDMO business unit – Crystal Formulation Services (CFS) has successfully passed a remote audit conducted by a US client. The audit, which lasted for four days, confirmed th...
2023-05-12 21:00
2658
Kintor Pharma Announces Successful Completion of Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the US
SUZHOU, China, May 11, 2023 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced that the Phase II clinical trial of in-house developed KX-826 for the treatm...
2023-05-11 23:30
3139
Fosun Pharma Participates in BEYOND Expo 2023 to Showcase Its Innovative R&D Achievements
MACAU, May 10, 2023 /PRNewswire/ -- From May 10 to 12, 2023, the 3rd BEYOND International Technology Innovation Expo — also known as BEYOND Expo 2023is being held at the Venetian Macau Convention and Exhibition Center. This year is the third consecutive year that Fosun Pharma (stock code: 600196....
2023-05-10 22:57
3885
CytoMed Therapeutics Limited Announces Collaboration with MD Anderson Cancer Center to Advance Allogeneic Off-the-Shelf Gamma Delta T Cells in Oncology
SINGAPORE, May 9, 2023 /PRNewswire/ -- CytoMed Therapeutics Limited (Nasdaq: GDTC) ("CytoMed" or the "Company"), a biopharmaceutical company focused on harnessing its licensed proprietary technologies to create novel allogeneic cell-based immunotherapies for the treatment of human cancers, today ...
2023-05-09 22:07
3297
PharmAbcine to participate in "BIO International Convention 2023"
DAEJEON, South Korea, May 8, 2023 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of fully human antibody therapeutics, announced today that the company will participate in the upcoming BIO International Convention 2023. Details...
2023-05-08 20:00
3310
Chance Pharmaceuticals and Acorda Therapeutics Announce Agreement to Provide INBRIJA® in Greater China
HANGZHOU, China, May 8, 2023 /PRNewswire/ -- Chance Pharmaceuticals and Acorda Therapeutics, Inc. today announced that they have entered into distribution and supply agreements to provide INBRIJA® in Greater China (Mainland China, Taiwan, Hong Kong, and Macao). INBRIJA is indicated in the United ...
2023-05-08 19:30
2085
Neuro3 Therapeutics Acquires Exclusive Worldwide Rights to Develop and Commercialize Clinical Stage KCNQ2 Activators from Lundbeck
CAMBRIDGE, Mass. and SUZHOU, China, May 8, 2023 /PRNewswire/ -- Neuro3 Therapeutics (Neuro3), a biotechnology company focused on the discovery and development of innovative medicines for the treatment of central nervous system (CNS) diseases, announced today the signing of an exclusive, worldwide...
2023-05-08 14:00
2128
BLISS BIOPHARMACEUTICAL ENTERS INTO A CLINICAL TRIAL COLLABORATION AGREEMENT WITH AN OPTION OF STRATEGIC COLLABORATION WITH EISAI FOR BB-1701
HANGZHOU, China, May 7, 2023 /PRNewswire/ -- Bliss Biopharmaceutical (Hangzhou) Co., Ltd, ("BlissBio") a clinical-stage biopharmaceutical company developing differentiated antibody-drug conjugate (ADC) therapeutics, announced a clinical trial collaboration agreement with option for strategic coll...
2023-05-08 07:00
2579
NEW THERAPY FOR RARE GASTROINTESTINAL STROMAL TUMOURS APPROVED IN SINGAPORE
* Singapore's Health Sciences Authority (HSA) has approved QINLOCK® (ripretinib) for the treatment of patients with 4th line GIST * QINLOCK significantly reduced the risk of disease progression or death by 85% and showed clinically meaningful overall survival in theINVICTUS Phase 3 Study1,2 ...
2023-05-08 04:00
2429
Suzhou GenAssist Therapeutic Co.,Ltd recently announced that its first base editing product, GEN6050, has submitted a pre-IND application to the FDA and has been accepted
SUZHOU, China, May 6, 2023 /PRNewswire/ -- Suzhou GenAssist Therapeutic Co.,Ltd recently announced its pre-IND application of their first base editing product, GEN6050 and the acceptance by the FDA. GEN6050 is an in vivo base editing drug that targets exon 50 skipping in the Duchenne muscular...
2023-05-06 21:00
5150
Empowering Innovation to the Global Market with Acro Certify
NEWARK, Del., May 5, 2023 /PRNewswire/ -- For many companies, entering the global market is a daunting challenge. These obstacles can come in various forms. Sometimes the problem is finding the right target customer base or establishing an appropriate quality management system and shipping logist...
2023-05-06 10:18
5463
CARsgen's CLDN18.2 mAb AB011 Achieves IND Clearance from the NMPA for the First-line Combination Treatment of Gastric Cancer
SHANGHAI, May 5, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced that AB011 in combination with atezolizumab monoclonal antibody, Roche'...
2023-05-05 20:50
4022
ProQure and Identiv Partner to Launch Innovative NFC Type 2 Tags for Large-Scale NFC Deployments
The partnership's new PQ201/201s series tags deliver premium features at a competitive price point PLEASANTON, Calif., May 5, 2023 /PRNewswire/ -- ProQure, a technology provider of IoT cloud management for physical objects, and Identiv, a global leader in physical security and secure identificat...
2023-05-05 18:00
2920
Formosa Pharmaceuticals and AimMax Therapeutics Announce the NDA Submission to the US FDA for APP13007 for the Treatment of Post-Operative Inflammation and Pain following Ocular Surgery
TAIPEI, May 4, 2023 /PRNewswire/ -- Formosa Pharmaceuticals, Inc. (6838.TWO) and AimMax Therapeutics, Inc. (United States) announce the submission of a New Drug Application to the United States Food & Drug Administration (US FDA) for APP13007, a novel aqueous nanosuspension formulation of the pot...
2023-05-05 08:00
2597
Recall Notice - SD Biosensor, Inc. requests discontinuation of use and disposal of specific Pilot™ COVID-19 At-Home Tests in the United States due to microbial contamination in the liquid buffer solution
SEOUL, South Korea, May 4, 2023 /PRNewswire/ -- SD Biosensor, Inc. today is requesting that consumers stop using and dispose of specific Pilot COVID-19 At-Home Tests inthe United States because potentially harmful bacteria were found in the tube with liquid inside (pouch 2 of the kits). The affe...
2023-05-05 04:00
2788
Week's Top Stories
Most Reposted
Agoda Launches Agoda Impact Lab at ASEAN Tourism Forum
[Picked up by 322 media titles]
2026-01-29 15:06
Wonder Raises USD 12 Million Venture Debt from HSBC Innovation Banking to Drive Growth and Expansion
[Picked up by 322 media titles]
2026-02-02 10:00
AI adoption is widespread, but developer confidence is still catching up, Agoda report finds
[Picked up by 310 media titles]
2026-02-03 11:00
Colebrook Bosson Saunders Officially Launches Lana, A Circular Ergonomic Laptop Stand for the Hybrid Generation
[Picked up by 303 media titles]
2026-02-03 12:00
Singapore Airshow 2026 Milestone Edition: 20 Years of Shaping the Aerospace Landscape as Asia-Pacific Drives Global Growth
[Picked up by 286 media titles]
2026-02-01 19:35